<DOC>
	<DOC>NCT00518921</DOC>
	<brief_summary>This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.</brief_summary>
	<brief_title>Capadenoson in Angina Pectoris</brief_title>
	<detailed_description />
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina, Stable</mesh_term>
	<criteria>The primary diagnosis is chronic stable angina of mildmoderate intensity as defined by the Canadian Cardiovascular Society Functional Class IIIII, in the presence of definitive coronary artery disease. Male or female subjects aged 35 to 75 years (if female, only if postmenopausal or permanently sterilized) Stable angina of mildmoderate intensity (Canadian class IIIII) with antianginal medication not changed for the last 5 weeks Inability to withdraw current antianginal therapy Inability to withdraw any concomitant therapy that would interfere with interpretation of study results</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>adenosin agonist</keyword>
	<keyword>chronic stable angina</keyword>
</DOC>